Abstract
Purpose
To determine whether BPE in preoperative breast MRI influences patients’ recurrence-free survival (RFS).
Methods
Between February 2010 and December 2011, 804 consecutive women with invasive breast cancer who had undergone preoperative breast MRI and curative cancer surgery were identified. BPE was visually graded by two reviewers. We determined the correlation between BPE grade and other clinicopathological variables, including age, adjuvant therapy, menopausal status, histologic grade, T stage, N stage, lymphovascular invasion, molecular subtype, surgical margin status, and mammographic density. A Cox proportional hazards model was used to analyze the effects of clinicopathological variables and radiological findings (BPE grade, mammographic density) on RFS.
Results
High BPE was associated with premenopausal status (Ps < 0.0001), higher mammographic density (Ps < 0.0001), progesterone receptor positivity (Ps = 0.039, 0.007, respectively), presence of lymphovascular invasion (Ps = 0.008, 0.001, respectively), and close surgical margin (Ps < 0.0001). Recurrences were observed in 75 patients after a mean follow-up period of 61.8 months (range 4–81 months). Non-minimal BPE grade (RFS hazard ratio = 3.086, P = 0.003 for reader 1; RFS hazard ratio = 2.221, P = 0.075 for reader 2) and T3 stage were associated with worse outcomes in postmenopausal women. In premenopausal women, non-minimal BPE grade by readers 1 and 2 did not affect the patients’ outcomes.
Conclusions
Increased BPE on preoperative breast MRI in postmenopausal women has potential as a predictor of poor RFS.
Similar content being viewed by others
References
Muller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, Claussen C (1997) Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 203(1):145–149
Kuhl CK, Bieling HB, Gieseke J, Kreft BP, Sommer T, Lultterbey G et al (1997) Healthy premenopausal breast parenchyma in dynamic contrast enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical phase dependency. Radiology 203(1):137–144
Reichenbach JR, Przetak C, Klinger G, Kaiser WA (1999) Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. J Comput Assist Tomogr 23(3):407–413
Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Garrido L (2005) Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging—initial observations. Radiology 235(1):36–41
Saftlas AF, Hoover RN, Brinton LA, Szklo M, Olson DR, Salane M et al (1991) Mammographic densities and risk of breast cancer. Cancer 67(11):2833–2838
Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675
Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA (2011) Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. AJR 196(1):218–224
DeMartini WB, Liu F, Peacock S, Eby PR, Gutierrez RL, Lehman CD (2012) Background parenchymal enhancement on breast MRI: impact on diagnostic performance. AJR 198(4):W373–W380
King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA (2011) Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 260(1):50–60
Uematsu T, Kasami M, Watanabe J (2011) Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer? Eur Radiol 21(11):2261–2267
Choi JS, Ko ES, Ko EY, Han BK, Nam SJ (2016) Background parenchymal enhancement on preoperative magnetic resonance imaging: association with recurrence-free survival in breast cancer patients treated with neoadjuvant chemotherapy. Medicine (Baltimore) 95(9):e3000
Morris EA, Comstock CE, Lee CH, et al. (2013) ACR BI-RADS magnetic resonance imaging. In: ACR BI-RADS Atlas, breast imaging reporting and data system. American College of Radiology, Reston.
Youk JH, Gweon HM, Son EJ, Kim JA, Jeong J (2013) Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemical profile. Breast Cancer Res Treat 138(1):119–126
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174
Söderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L (1997) Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 176(1 Pt 1):123–128
Ko ES, Lee BH, Choi HY, Kim RB, Noh WC (2011) Background enhancement in breast MR: correlation with breast density in mammography and background echotexture in ultrasound. Eur J Radiol 80(3):719–723
Cubuk R, Tasali N, Narin B, Keskiner F, Celik L, Guney S (2010) Correlation between breast density in mammography and background enhancement in MR mammography. Radiol Med (Torino) 115(3):434–441
Sogani J, Morris EA, Kaplan JB, D’Alessio D, Goldman D, Moskowitz CS et al (2017) Comparison of background parenchymal enhancement at contrast-enhanced spectral mammography and breast MR imaging. Radiology 282(1):63–73
Folkman J (1995) Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333(26):1757–1763
Bhatelia K, Singh K, Singh R (2014) TLRs: linking inflammation and breast cancer. Cell Signal 26(11):2350–2357
Dontchos BN, Rahbar H, Partridge SC et al (2015) Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk? Radiology 276(2):371–380
Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76(1):27–36
Horwitz KB, McGuire WL (1978) Estrogen control progesterone receptor in human breast cancer: correlation with nuclear processing of estrogen receptor. J Biol Chem 253(7):2223–2228
Purdie CA, Quinlan P, Jordan LB et al (2014) Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer 110(3):565–572
Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26(7):1059–1065
Chatterton RT Jr, Lydon JP, Mehta RG et al (2002) Role of progesterone receptor (PR) in susceptibility of mouse mammary gland to 7, 12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett 188(1–2):47–52
Conneely OM, Jericevic BM, Lydon JP (2003) Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 8(2):205–214
Kougioumtzi A, Tsaparas P, Magklara A (2014) Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells. PLoS ONE 9(6):e98404
Scaranelo AM, Carrillo MC, Fleming R, Jacks LM, Kulkarni SR, Crystal P (2013) Pilot study of quantitative analysis of background enhancement on breast MR images: association with menstrual cycle and mammographic breast density. Radiology 267(3):692–700
Melsaether A, McDermott M, Gupta D, Pysarenko K, Shaylor SD, Moy L (2014) Inter- and intrareader agreement for categorization of background parenchymal enhancement at baseline and after training. AJR 203(1):209–215
Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738–2746
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
The requirement for patients’ informed consent was waived by the IRB.
Rights and permissions
About this article
Cite this article
Lim, Y., Ko, E.S., Han, BK. et al. Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer. Breast Cancer Res Treat 163, 573–586 (2017). https://doi.org/10.1007/s10549-017-4217-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4217-5